http://www.lsis.com/goto/r108/rss 2010-06-23T11:11:06+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97f%FB%16zyx It has been reported that bevacizumab in combination with paclitaxel significantly prolongs progression-free survival compared with paclitaxel alone in the initial treatment for metastatic breast cancer. To understand how bevacizumab enhances the efficacy of paclitaxel, we investigated the mechanism in a MX-1 human breast cancer xenograft model. The antitumor activity of bevacizumab at 5 mg/kg in combination with paclitaxel at 20 or 30 mg/kg was significantly higher than that of either agent alone. First, we measured the paclitaxel concentration in tumor to see whether bevacizumab enhances the activity by increasing the tumor concentration of paclitaxel. When given in combination with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97f%FC%12%7Cv%7B MADISON, Wis.-(BUSINESS WIRE)-Roche NimbleGen (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) is pleased to announce that imaGenes GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for Comparative Genomic Hybridization (CGH). imaGenes is a solution provider for functional genomics and proteomics with a comprehensive portfolio of high-quality services for molecular life sciences. This is the third Roche NimbleGen certification for imaGenes to provide service for NimbleGen arrays. This follows the successful certification for ChIP-chip in December 2009 and DNA methylation analysis in February 2010, and makes imaGenes the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97f%FC%13%7Bzx The objective of this study was to predict R(b) (blood/plasma ratio) in humans using a simple method. Human and rat R(b) and free fraction in plasma (f(p) values were obtained from the literature. The ratio of total red blood cell concentration to the free concentration in plasma (K(b) was calculated using f(p) and R(b). Four methods were used for the prediction of R(b): (A) use of rat R(b); (B) use of R(b) calculated from rat K(b) and human f(p); (C) correlation of human log (1-f(p)/f(p) and human log K(b); and (D) correlation of log D with human log K(b). The R(b) of 96 compounds in humans ranged from 0.52 to 2.00, with an average of 0.89. A significant correlation was observed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97f%FC%10zy%7C Fluorescein isothiocyanate (FITC)-labeled antibodies are widely used as primary antibodies in the tissue cross-reactivity (TCR) studies for the development of therapeutic antibodies. However, the effects of FITC-labeling on the characteristics of an antibody are poorly understood. The present study was performed to examine the effect of FITC-labeling on the binding affinity and immunohistochemical staining profile of an antibody, using several antibodies with different FITC-labeling indices. The results showed that the FITC-labeling index in antibody was negatively correlated with the binding affinity for its target antigen. Immunohistochemically, an antibody with a higher labeling index (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97f%FD%1Ct%7Fy CAMBRIDGE, Mass., Jun 16, 2010 (BUSINESS WIRE) - Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin(R) (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients. Roche has informed Curis that the trial did not meet its primary endpoint of extending the time from randomization to disease progression (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97f%FE%12%7D%7D%7E PENZBERG, Germany-(BUSINESS WIRE)-The 3Rs concept of reducing, refining and replacing animal experimentation was developed by W.M.S. Russell and R.L. Burch in their book œThe Principles of Humane Experimental Technique  more than 50 years ago. Today, early identification of toxic compounds using cell-based in vitro assays like Roche s (SIX: RO, ROG; OTCQX: RHHBY) xCELLigence System can reduce the number of laboratory animals used for in vivo testing of suboptimal compounds that ultimately fail at later stages of drug testing. A recent study from Roche Pharma and Roche Applied Science (1) describes a comprehensive workflow of in vitro techniques, including real-time cell analysis, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97f%FE%15%7Fwr PENZBERG, Germany-(BUSINESS WIRE)-Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have studied the involvement of œmicrotentacles,  or extensions of the plasma membrane of breast cancer cells, in how cancers spread to distant locations in the body (1). Targeting these microtentacles might prove to be a new way to prevent or slow the growth of these secondary cancers, scientists say. The researchers used Roches s (SIX: RO, ROG; OTCQX: RHHBY) xCELLigence RTCA SP Instrument to measure attachment as the relative impedance change, cell index, across the microelectronic sensors at the bottom of the system s E-Plates. We hope that through our research, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97f%FF%17t%7Cr Roche Holding AG, and its subsidiaries Genentech Inc and Chugai Pharmaceutical Co Ltd, are developing trastuzumab emtansine (trastuzumab-DM1) for the treatment of HER2+ metastatic breast cancer. Trastuzumab emtansine is a tumor-activated prodrug resulting from the conjugation of the humanized anti-HER2 mAb trastuzumab, which has been used in the treatment of breast cancer for over 10 years, with ImmunoGen Inc's cytotoxic and antimitotic maytansine derivative DM1. The maytansinoids bind microtubules in a manner similar to the vinca alkaloids; however, maytansinoids have been recognized to be 20- to 100-fold more potent at blocking mitosis. Nevertheless, the use of these compounds as single (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%F6%10%7Ey%7B PENZBERG, Germany-(BUSINESS WIRE)-G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology. Roche Applied Science (SWX:RO)(SWX:ROG)(Pink Sheets: RHHBY) partnered with ATCC to research real-time endogenous GPCR function using the xCELLigence System from Roche and cells from ATCC. (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v108/%3B%97g%F7%1Dxx%7F Roche Diagnostics announced that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma. Roche received approvals for the anti-HCV test on three platforms: the stand-alone cobas e 411 analyzer for low-volume testing; and the cobas e 601 and MODULAR ANALYTICS E 170 analyzers, which are modules of consolidated immunoassay/clinical chemistry systems for mid-volume and high-volume testing, respectively. The anti-HCV assay is an 18-minute test designed for use with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%F7%10%7Ez%7C BRANFORD, Conn. & BASEL, Switzerland-(BUSINESS WIRE)-Roche (Pink Sheets:RHHBY) (SWX:RO) (SWX:ROG), announced today the global launch of the GS Junior System, the company s new benchtop next-generation DNA sequencing platform for life science research. The GS Junior System, developed by 454 Life Sciences, a Roche company, provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size, efficiency and price competitiveness, thousands of small and medium sized research laboratories worldwide will now have access to Roche s state-of-the-art sequencing capabilities at an affordable price. Roche has a proven (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97g%F9%17uxr Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III PRIMA study. The data showed that continuing MabThera (rituximab) for two years in patients who responded to initial treatment with MabThera plus chemotherapy, doubled the likelihood of them living without their disease worsening, known as progression-free survival (PFS), compared to those who did not receive maintenance. The study enrolled patients with previously untreated advanced follicular lymphoma. No new safety signals were observed in this study and the safety profile was consistent with previous experience with MabThera. The data were featured during an American Society of Clinical Oncology (ASCO) presscast (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%F9%14u%7Er DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2e0bae/lymphoma_therapeut) has announced the addition of the "Lymphoma Therapeutics - Global Strategic Business Report" report to their offering. Lymphoma Therapeutics - Global Strategic Business Report This report analyzes the worldwide markets for Lymphoma Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 93 companies including many key and niche players such as Allos Therapeutics, Inc., Astellas Pharma US, Inc., Biogen (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%F9%14tvx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0479b5/anemia_drugs_glo) has announced the addition of the "Anemia Drugs - Global Strategic Business Report" report to their offering. Anemia Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Anemia Drugs in US$ Million by the following segments: Short Acting ESAs (Erythropoiesis Stimulating Agents), and Long Acting ESAs (Erythropoiesis Stimulating Agents). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97g%FA%12tx%7B BASEL, Switzerland & CAMBRIDGE, Mass., May 19, 2010 (BUSINESS WIRE) - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec /quotes/comstock/15*!biib/quotes/nls/biib (BIIB 50.70, +0.13, +0.26%) today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA). Following a detailed analysis of the efficacy and safety results from the RA programme, the companies concluded that the overall benefit to risk profile of ocrelizumab was not favourable in RA taking into account the currently available treatment options. The ocrelizumab RA program included four Phase III studies (SCRIPT, FILM, FEATURE, and STAGE). Most recent (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97g%FA%12%7By%7C IRVING, TX, May 19, 2010 - Caris Life Sciences ¢, a leading biosciences company focused on driving precise and personalized healthcare, today announced that Jonathan Knowles, Ph.D., will assume the role of Chief Scientific Officer for the company. This newly-created position highlights Caris growth and expansion into novel diagnostic, prognostic and theranostic technologies, led by the ongoing development and commercialization of the Carisome ¢ platform - a proprietary, blood-based technology being developed for rapid and accurate testing for cancer and other complex diseases. As Chief Scientific Officer, Dr. Knowles assumes responsibility for the expansion and globalization of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97g%FA%11t%7Cz MR16-1 is a monoclonal antibody to mouse IL-6 receptor (IL-6R) and a good tool to investigate the involvement of IL-6 in mouse disease models. However, long-term administration of MR16-1 induced anti-MR16-1 antibody that inhibited IL-6 blocking activity of MR16-1. In this study, we treated NZB/NZW F1 (BWF1) mice with MR16-1 (0.5 mg, weekly) and tested for proteinuria (an indicator of autoimmune disease) after inducing tolerance by intraperitoneal injection of anti-CD4 mAb, or in an exploratory experiment, by prior intravenous injection of 2 mg MR16-1. Anti-CD4 mAb treatment inhibited anti-MR16-1 antibody production. And the appearance of proteinuria was significantly delayed. However, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%FB%10u%7C%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/95fc7f/anemia_drug_pipe) has announced the addition of GlobalData 's new report "Anemia - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering. Anemia - Drug Pipeline Analysis and Market Forecasts to 2016 "Anemia - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%FD%13x%7C%7E CAMBRIDGE, Mass.-(BUSINESS WIRE)-Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010. All of Curis key development programs have made significant progress since the beginning of 2010 œAll of Curis key development programs have made significant progress since the beginning of 2010,  said Dan Passeri, Curis President and Chief Executive Officer. œWe recently completed our Phase I dose escalation study of CUDC-101 and believe that the maximum tolerated dose observed in this study has the potential to provide a (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v108/%3B%97g%FF%12zz%7F SAN FRANCISCO, CA-(Marketwire - April 29, 2010) - BioCentury Publications, Inc. has awarded the "SEED Winner's Tour" to the top winners of the SEED Life Science Business Plan Competition in Shanghai. The SEED (Scientists to Entrepreneurs, Education and Development) Competition was organized by Roche, OrbiMed Advisors and McKinsey & Company, and hosted by ChinaBio Accelerator. It marked the first life science business plan competition in China, designed to help entrepreneurs and academicians create life science and healthcare companies, enhance technology transfer and commercialization capabilities across the scientific community and establish a commercialization platform for innovator (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v108/%3B%97g%FF%12xvx Roche and the International Atomic Energy Agency (IAEA) announced today the launch of the EDUCARE (EDUcation for Cancer in African REgions) project to provide concerted support to help combat the growing cancer epidemic in sub-Saharan Africa. The EDUCARE project is to be piloted in Ghana, Tanzania, Uganda and Zambia, and is linked with the IAEA s wider initiative to build regional training networks in cancer control and a Virtual University for Cancer Control (VUCCnet) in Africa. The IAEA is working in collaboration with the World Health Organization (WHO) and other international partners to develop the VUCCnet across Africa. The EDCUARE project will facilitate a first-of-its-kind exchange (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%FF%12%7F%7E%7F PENZBERG, Germany-(BUSINESS WIRE)-Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents. Viability and cytotoxicity assays are routinely used to determine how various treatments potentially perturb cell homeostasis leading to decreased viability and increased cytotoxicity. Many agents used for cancer therapeutics modulate the intricate balance between cell proliferation and cell death. The (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%FF%16t%7By DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/229444/pharmaceuticals_in) has announced the addition of the "Pharmaceuticals in Japan" report to their offering. The Pharmaceuticals in Japan industry profile is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information. Scope Contains an executive summary and data on value, volume and/or segmentation Provides textual analysis of Pharmaceuticals in Japan's recent performance and future (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%FF%15xys DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their stem cell research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - for example, how important is this person in a specific medical research specialization The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 130,760 individuals working in stem cell research. (http:/tinyurl.com/3xhs4pj) Top 10 Countries for Stem Cell Research (ranked by (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97g%FF%15%7Fzz MADISON, Wis.-(BUSINESS WIRE)-Sequence Capture technology was pioneered by Roche NimbleGen (Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) with the initial products focused on human research. Subsequent developments have enabled the technology to be successfully transferred to rice and then adapted to maize. In January 2009, Roche NimbleGen and Biogemma announced their collaboration to develop a NimbleGen Sequence Capture protocol adapted to crops containing more complex genomes including polyploid crops such as wheat and rapeseed (canola). The goal of this partnership was to enhance capture performance on these complex species in order to achieve an enrichment rate that makes downstream (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%F6%1C%7C%7Ds We examined the therapeutic effect of high molecular weight hyaluronic acid (HA) on the progression of joint pain and cartilage degeneration in a rabbit osteoarthritis (OA) model. The OA model was induced by partial meniscectomy. In the time course study, cartilage degeneration was assessed at 3, 7 and 14 days after operation. In the therapeutic study, HA or loxoprofen (LOX) was administered for 14 days beginning four days after operation (after the onset of knee pain and cartilage degeneration). Knee pain was assessed by weight distribution on the hind paw, and cartilage damage and MMP production in the joints were evaluated 18 days after surgery. In the time course study, severe (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%F7%13%7Bv%7C Multivariate statistical methods are commonly used in the analysis of quantitative structure-activity/property relationships (QSAR and QSPR, respectively). The partial least squares (PLS) method is of particular interest because it can analyze data containing numerous X variables with strongly collinear and noisy characteristics and can simultaneously model several response variables Y. Furthermore, it can provide us with several prediction regions and diagnostic plots as statistical measures. PLS has evolved or changed for coping with the severe demands associated with the complex data structures of X and Y variables. In this review article, we selected five advanced PLS techniques and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%F7%17%7F%7Fx Eldecalcitol is a vitamin D(3) analog under clinical development for the treatment of osteoporosis. Previous studies have shown that the binding activities of eldecalcitol to the serum vitamin D binding protein (DBP) and the vitamin D receptor (VDR) are 421.9% and 44.6% of those of calcitriol, respectively, and also, suppressed parathyroid hormone (PTH) production by only 3.5% of calcitriol in vitro using bovine parathyroid cell primary culture. Here, we compared in vivo activities of eldecalcitol on serum calcium, BMD and PTH with those of calcitriol. Six-week old male rats were given either vehicle (medium chain triglyceride; n=6), eldecalcitol (0.025, 0.05, 0.1, 0.25, 0.5mug/kg; n=6) or (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%F7%15%7C%7C%7C In the present study, we investigated potential synergism between IL-6 and IL-1 for the production of matrix metalloproteinases (MMPs) by the synovial cell line SW982. Cells were cultured with different combinations of IL-6, soluble IL-6 receptor (sIL-6R) and IL-1beta for 24h and production of MMPs was then measured. IL-6+sIL-6R, but not IL-6 alone, induced MMP-13 and MMP-3 production. IL-1beta also induced production of MMPs. Of interest, addition of IL-6+sIL-6R together with IL-1beta synergistically increased MMP production. Next, we analyzed the mechanism responsible for the synergistic effects of IL-6+sIL-6R and IL-1beta in combination. IL-1beta-induced MMP production was significantly (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%F8%16%7B%7C%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3a1f8b/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Antivirals" to their offering. In February 2010, Roches CEO, Severin Schwan, reported that Tamiflu (oseltamivir) sales increased 435% over sales in 2008. Tamiflu sales were 3.2 billion Swiss francs ($3 billion) in 2009 and accounted for 7% (2.6 billion francs, $2.4 billion) of the pharmaceutical divisions sales growth the divisions sales growth was 4% without Tamiflu. This high percentage of growth was due to the global demand for antivirals active against pandemic influenza (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%F9%1C%7Ev%7D A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently. |-| Bioorg Med Chem. |-| Yoshino H, Sato H, Tachibana K, Shiraishi T, Nakamura M, Ohta M, Ishikura N, Nagamuta M, Onuma E, Nakagawa T, Arai S, Ahn KH, Jung KY, Kawata H. |-| Research Division, Chugai (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FA%1C%7F%7Cs BRANFORD, Conn.-(BUSINESS WIRE)-As part of a semester-long course which aims to investigate the health of California sea lions and their environment, a group of undergraduate students at San Diego State University are experiencing first-hand the sequencing technology that is revolutionizing life science research. Led by SDSU Professor Elizabeth Dinsdale, the university students are learning how to prepare DNA samples and operate the Genome Sequencer FLX System, a high-throughput sequencing platform from 454 Life Sciences, a Roche Company. Along with their wetlab lessons on molecular biology and sequencing techniques, the students have a much larger goal in mind: to sequence the complete (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%FA%12y%7B%7B In quantitative structure-activity relationship (QSAR) and quantitative structure-property relationship (QSPR), there is a considerable interest in support vector machine (SVM) and support vector regression (SVR) for data modeling. SVM and SVR have a high performance for classification and regression rates, but their chemical interpretations are not feasible. In this review, we present some promising approaches to visualize and interpret the SVM and SVR models. This type analysis would be useful for molecular design. Representative examples derived from chemoinformatics and bioinformatics are highlighted in detail. We also refer to a structure generator based on SVR score in the framework (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%FA%10%7E%7C%7D Purpose: A high-throughput formulation screening (HTFS) system that enabled to rapidly and efficiently select self-microemulsifying drug delivery system (SMEDDS) formulations has been developed in our previous study. The purpose of this study was to investigate the applicability of the HTFS system to SMEDDS designs. Methods: A poorly soluble drug (Nilvadipine), an oil (Sefsol-218), 11 hydrophilic surfactants (HS), and 10 lipophilic surfactants (LS) were used. Formulations were prepared and SMEDDS formulations were chosen by the HTFS system. A HS with the largest number of SMEDDS formulations was selected. In the selected HS system, a LS with the largest number of SMEDDS formulations was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%FA%14t%7D%7D CHI's 17th International Tri-Conference on Molecular Medicine, held in San Francisco, included topics covering new developments in the field of medicinal chemistry. This conference report highlights selected presentations on fragment-based drug discovery, quantum mechanical energy decomposition for the analysis of SARs, medicinal chemistry strategies and the role of imaging in drug discovery. Investigational drugs discussed include MLN-4924 (Millennium Pharmaceuticals Inc), GDC-0449 (Chugai Pharmaceutical Co Ltd/Curis Inc/F Hoffmann-La Roche Ltd/Genentech Inc/NCI), RDEA-119 (Ardea Biosciences Inc/Bayer HealthCare AG) and tafamidis (Fx-1006A; FoldRx Pharmaceuticals Inc). |-| IDrugs. |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v108/%3B%97%60%FD%15%7C%7Bs To date, there have been no reports showing the efficacy of nonsecosteroidal vitamin D receptor (VDR) agonists in a benign prostatic hyperplasia (BPH) animal model. To examine the efficacy of CH5036249, a novel nonsecosteroidal VDR agonist, we orally administered the compound at 0.03mug/kg to a beagle model with spontaneous BPH. Prostate volume was checked by rectal ultrasonic probe periodically during 11 months of administration and the prostate tissues histologically examined. CH5036249 inhibited prostate growth in two out of three dogs compared with vehicle-treated dogs. In the prostate specimens, substantial atrophy of the epithelium was observed in all dogs administered CH5036249. At (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FF%1C%7Fv%7B PENZBERG, Germany-(BUSINESS WIRE)-Roche (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) and Ghent University (Belgium) have signed an agreement for the use of Roche's LightCycler 1536 Instrument in various cancer research projects in Ghent. Studies include multigene expression signature profiling on cancer research samples and, digital PCR for sensitive detection of mutant cancer cells in a background of normal cells. Furthermore, DNA methylation analysis studies, copy number variant screening (CNV), and amplicon generation for next generation sequencing are part of the planned experiments. One potentially groundbreaking study is a qPCR based transcriptome-wide profiling, which represents a tremendous (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97%60%FF%12uzx MADISON, Wis.-(BUSINESS WIRE)-Roche NimbleGen is pleased to announce that its Service Business (via its Iceland service facility, located in Reykjavik, Iceland), will now offer 2 micron resolution scanning on the NimbleGen MS 200 Microarray Scanner for Comparative Genomic Hybridization arrays (2.1M, 3x720K, and 12x135K formats) and Gene Expression arrays (12x135K format). The NimbleGen MS 200 Microarray Scanner is the latest enhancement to the Roche NimbleGen microarray workflow and provides high throughput processing optimized for current high resolution NimbleGen microarrays as well as the next-generation NimbleGen arrays of tomorrow. The increase in resolution to 2 micron scanning in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97%60%FF%10%7F%7F%7E MADISON, Wis.-(BUSINESS WIRE)-Roche NimbleGen (SWX:RO - News) (SWX:ROG - News) (Pink Sheets:RHHBY - News), announced today a company-wide initiative to implement Good Manufacturing Processes (GMP) for its suite of DNA microarrays. The implementation of GMP will cover the full scope of processes from development through manufacturing and will include all locations. The company plans on achieving GMP compliance followed by subsequent submission for clearance or approval of select array products to the US Food and Drug Administration. œRoche is dedicated to providing the research, diagnostic, and pharmaceutical markets with the highest quality products possible,  said Dr. Frank Pitzer, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FF%11uvy SUNNYVALE, Calif.-(BUSINESS WIRE)-Supply market volatility. Capacity constraints. Global uncertainty. They re the reality of doing business in the New Normal that all companies must deal with. Add to this calls for reform, regulatory uncertainty, competition from generic drugs, shrinking R&D pipelines and declining demand for elective procedures, and the reality becomes even more complex for healthcare concerns. On May 25, executives from top providers, producers, payers, and distributors will discuss these challenges and ways in which they can collaborate to overcome them during a Townhall Meeting at Ariba LIVE (www.aribalive.com), the premier conference for anyone engaged in buying, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FF%11%7C%7Dz BRANFORD, Conn.-(BUSINESS WIRE)-A study published online today in the journal Genome Research offers surprising new clues into the genomic complexity of the giant Mimivirus, the largest known virus in the world. Previous studies have shown that unlike most viruses, the Mimivirus has more genes than many bacteria and performs functions that normally occur only in cellular organisms. The results of the most recent study, led by a team from the Structural and Genomic Information Laboratory at the Mediterranean Institute of Microbiology in Marseille, France, suggest that the Mimivirus is even more complex than previously thought. Using the Genome Sequencer FLX System from 454 Life Sciences, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FF%16y%7E%7F PENZBERG, Germany-(BUSINESS WIRE)-In a recent study initiated by Beiersdorf AG (1), Florian Spörl and colleagues evaluated the use of Roche Applied Science s (Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes. This real-time cell analysis system measures alterations in cellular impedance using microelectrodes on the surface of a 96-well culture plate (E-Plate). Spörl et al. were (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97%60%FF%16x%7D%7F INDIANAPOLIS, March 30 /PRNewswire/ - Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) has granted CLIA-waived status to the CoaguChek XS Plus system, a point-of-care anticoagulation monitor that offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing. The waiver means that the monitoring technology may now be used in a broader range of clinical settings, such as labs that do not meet the requirements to do moderate- or high-complexity testing as defined by the Clinical Laboratory Improvement Amendments (CLIA) of 1988. "With the waiver for the CoaguChek XS Plus system, healthcare (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97%60%FF%14%7E%7Ey MADISON, Wis.-(BUSINESS WIRE)-Roche NimbleGen (SWX:RO - News)(SWX:ROG - News)(Pink Sheets:RHHBY - News), a global leader in microarray tools for genetic discovery and analysis, announced today that Frank Pitzer has been appointed as CEO. Dr. Pitzer s extensive background and experience of over eight years at Roche will be instrumental in guiding the company through its next stage of growth. With his successful track record in several key management positions within Roche Diagnostics, he brings a wealth of organizational, commercial, and relevant operating experience in key areas impacting the genomics and life science industry today. Dr. Pitzer most recently served as Head of Divisional (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FF%15u%7E%7B MADISON, Wis.-(BUSINESS WIRE)-In a recently published study in the journal Genome Research, a team of scientists led by Dr. Shaying Zhao at the University of Georgia have developed a novel cross-species comparative genomics and oncology strategy for cancer driver gene discovery, using microarray technologies from Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY), that differs fundamentally from current approaches which focus on human cancers only. This study used NimbleGen CGH arrays to pinpoint genes likely responsible for colorectal cancer (CRC) by identifying genomic copy number abnormalities (CNAs) that are common in both canine and human CRC research samples (Genome Research, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97%60%FF%15xv%7F BRANFORD, Conn.-(BUSINESS WIRE)-At the analytica conference today in Munich, Germany, a group of early access users shared their first results using the GS Junior System, a new bench top high-throughput sequencing platform for life science research use from 454 Life Sciences, a Roche Company (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY). The presentations, which ranged from studies on targeted amplicon sequencing to whole genome sequencing of bacterial genomes, underscore the speed at which the researchers were able to progress from hypothesis to biologically relevant results. One of the most exciting aspects of the GS Junior System for our lab is the low barrier cost to running smaller, pilot (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97a%F6%13%7C%7Dz MADISON, Wis.-(BUSINESS WIRE)-Researchers from Iowa State University, University of Minnesota, University of Florida and Roche NimbleGen (SIX:RO)(SIX:ROG)(Pink Sheets:RHHBY) have published a novel method to perform targeted sequencing in the highly complex maize genome. The method, which can be easily adapted to other genomes including partially sequenced genomes, has the potential to revolutionize genetic studies in agriculturally important species with a goal of leading to more robust and safer crops. Substantial public investments in crop genomics have simplified the process of identifying chromosomal regions and genes that regulate agriculturally important traits. NimbleGen Sequence (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v108/%3B%97a%F6%15%7Cy%7C TOKYO, March 16 /PRNewswire/ - Astellas Pharma Inc. today notified OSI Pharmaceuticals Inc. that it will nominate a full and competing slate of independent directors at OSI Pharmaceuticals' 2010 annual stockholders' meeting.On March 2, 2010, Astellas commenced a tender offer to acquire all of the outstanding shares of OSI for $52.00 per share in cash. This price represents a significant premium of over 40% to OSI's unaffected closing price of $37.02 per share on February 26, 2010 and a 53% premium to its three-month average as of the same date of $34.01. The tender offer is not subject to any financing conditions or due diligence and only contains customary conditions to (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v108/%3B%97a%F7%1Cty%7F TOKYO, March 16 /PRNewswire/ - Astellas Pharma Inc. (TSE: 4503) today notified OSI Pharmaceuticals Inc. (Nasdaq: OSIP) that it will nominate a full and competing slate of independent directors at OSI Pharmaceuticals' 2010 annual stockholders' meeting. This highly-qualified slate of directors proposed by Astellas is composed of Martin Edelshain, Cono R. Fusco, Michael A. Griffith, Jill Kanin-Lovers, Jack Kaye, Douglas E. Linton, Timothy P. Lynch, Jonathan R. Macey, Heidi L. Steiger, and Joseph L. Turner. On March 2, 2010, Astellas commenced a tender offer to acquire all of the outstanding shares of OSI for $52.00 per share in cash. This price represents a significant premium of over 40% to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v108/%3B%97a%F7%1Cy%7C%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/013fbe/rheumatoid_arthrit) has announced the addition of the "Rheumatoid Arthritis Therapeutics - Global Strategic Business Report" report to their offering. Rheumatoid Arthritis Therapeutics - Global Strategic Business Report This report analyzes the worldwide markets for Rheumatoid Arthritis Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, Latin America and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 103 companies including many key and niche players worldwide such as Abbott (…)